Alternative therapies and future intervention for treatment of membranous nephropathy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in Nephrology

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0270-9295(03)00047-0PMID 12923724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Membranous nephropathy

  2021cited by this paper
• T cells in the pathogenesis of systemic lupus erythematosus.

  2004cited by this paper
• Bone Morphogenetic Protein-7 Inhibits Constitutive and Interleukin-1β-Induced Monocyte Chemoattractant Protein-1 Expression in Human Mesangial Cells: Role for JNK/AP-1 Pathway 1

  2003cited by this paper
• TGF-beta signal transduction and mesangial cell fibrogenesis.

  2003cited by this paper
• TGF-β signal transduction and mesangial cell fibrogenesis

  2003cited by this paper
• Exploring the connection between chronic renal fibrosis and bone morphogenic protein-7.

  2003cited by this paper
• Complement inhibitors and glomerulonephritis: are we there yet?

  2003cited by this paper
• Eculizumab (Alexion).

  2002cited by this paper
• Novel concepts in understanding and management of glomerular proteinuria.

  2002cited by this paper
• Rituximab for idiopathic membranous nephropathy.

  2002cited by this paper
• Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease.

  2002cited by this paper
• Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis.

  2002cited by this paper
• Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis.

  2002cited by this paper
• Treatment of chronic tubulointerstitial disease: a new concept.

  2002cited by this paper
• Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.

  2002cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• Apoptosis and Myofibroblast Expression in Human Glomerular Disease: A Possible Link with Transforming Growth Factor-Beta-1

  2002cited by this paper
• Development of anti-TNF therapy for rheumatoid arthritis

  2002cited by this paper
• A multicenter, open‐label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney–pancreas transplant recipients: interim analysis

  2002cited by this paper
• Mycophenolate mofetil treatment for primary glomerular diseases.

  2002cited by this paper
• New approaches to delay the progression of chronic renal failure.

  2002cited by this paper
• Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function.

  2002cited by this paper
• Interleukin-1β stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-β-dependent mechanism

  2002cited by this paper
• Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism.

  2002cited by this paper
• Effects of C‐reactive protein and pentosan polysulphate on human complement activation

  2002cited by this paper
• Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System Inhibition

  2002cited by this paper
• Structural aspects and design of low-molecular-mass complement inhibitors.

  2001cited by this paper
• Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha.

  2001cited by this paper
• DOSE OPTIMIZATION OF MYCOPHENOLATE MOFETIL WHEN ADMINISTERED WITH A LOW DOSE OF TACROLIMUS IN CADAVERIC RENAL TRANSPLANT RECIPIENTS

  2001cited by this paper
• Connective tissue growth factor: an attractive therapeutic target in fibrotic renal disease

  2001cited by this paper
• Advances in the treatment of lupus nephritis.

  2001cited by this paper
• Use of pentoxifylline in membranous nephropathy.

  2001cited by this paper
• Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

  2001cited by this paper
• Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis

  2000cited by this paper
• T cells in the pathogenesis of systemic lupus erythematosus: Potential roles of CD154-CD40 interactions and costimulatory molecules

  2000cited by this paper
• Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

  2000cited by this paper
• Use of mycophenolate mofetil in resistant membranous nephropathy.

  2000cited by this paper
• Treatment with Mycophenolate Mofetil Attenuates the Development of Heymann Nephritis

  2000cited by this paper
• Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.

  2000cited by this paper
• Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages.

  1999cited by this paper
• Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.

  1999cited by this paper
• Prediction Equation for Glomerular Filtration Rate

  1999cited by this paper
• Pentosan Polysulfate Decreases Proliferation and Net Extracellular Matrix Production in Mouse Mesangial Cells

  1999cited by this paper
• Pentoxifylline Inhibits TNF- α Production from Human Alveolar Macrophages

  1999cited by this paper
• A two-step, two-signal model for the primary activation of precursor helper T cells.

  1999cited by this paper
• The soluble CD40 ligand sCD154 in systemic lupus erythematosus.

  1999cited by this paper
• The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy

  1999cited by this paper
• Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis.

  1999cited by this paper
• Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate.

  1999cited by this paper
• Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells.

  1999cited by this paper
• CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

  1999cited by this paper
• The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension.

  1999cited by this paper
• Pathophysiology of progressive nephropathies.

  1998cited by this paper
• Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy

  1998cited by this paper
• Complement regulatory proteins in glomerular diseases.

  1998cited by this paper
• The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart.

  1998cited by this paper
• Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis.

  1998cited by this paper
• Adhesion molecules and urinary tumor necrosis factor-alpha in idiopathic membranous glomerulonephritis.

  1998cited by this paper
• Successful mycophenolate mofetil treatment of glomerular disease.

  1998cited by this paper
• Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.

  1998cited by this paper
• In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation.

  1998cited by this paper
• Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition.

  1998cited by this paper
• Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein.

  1997cited by this paper
• Reduction in circulating dsDNA antibody titer after administration of LJP 394.

  1997cited by this paper
• Inhibition of human interleukin‐12 production by pentoxifylline

  1997cited by this paper
• Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

  1997cited by this paper
• RANTES and Monocyte Chemoattractant Protein–1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis

  1997cited by this paper
• Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

  1997cited by this paper
• Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis

  1996cited by this paper
• Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy.

  1996cited by this paper
• A central role of CD40 ligand in the regulation of CD4+ T-cell responses.

  1996cited by this paper
• A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone.

  1996cited by this paper
• Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

  1996cited by this paper
• Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy.

  1996cited by this paper
• The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.

  1996cited by this paper
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

  1996cited by this paper
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  1996cited by this paper
• Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.

  1995cited by this paper
• Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins.

  1995cited by this paper
• Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.

  1995cited by this paper
• A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group.

  1995cited by this paper
• Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.

  1995cited by this paper
• Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: beneficial effects in sepsis syndrome

  1995cited by this paper
• Long-term effects of antihypertensive agents on proteinuria and renal function.

  1995cited by this paper
• Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria.

  1995cited by this paper
• Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy.

  1995cited by this paper
• Tubulointerstitial lesions in human membranous glomerulonephritis: relationship to proteinuria.

  1995cited by this paper
• Cytokines, Phagocytes, and Pentoxifylline

  1995cited by this paper
• Structure and function of podocytes: an update

  1995cited by this paper
• Urinary tumor necrosis factor levels in primary glomerulopathies.

  1994cited by this paper
• Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.

  1994cited by this paper
• Pentosan‐induced thrombocytopenia: support for an immune complex mechanism

  1994cited by this paper
• Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis

  1993cited by this paper
• [Immunoglobulins or plasma exchange? Synchronization of plasma exchange and intravenous polyvalent immunoglobulins. A consecutive study of 11 patients].

  1993cited by this paper
• Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.

  1993cited by this paper
• Prognosis of untreated patients with idiopathic membranous nephropathy

  1993cited by this paper
• Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy.

  1993cited by this paper
• Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients

  1993cited by this paper
• Anti-idiotype antibodies to anti-myeloperoxidase autoantibodies in patients with systemic vasculitis.

  1993cited by this paper

• Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy

  2025cites this paper
• Yi Shen An, a Chinese traditional prescription, ameliorates membranous glomerulonephritis induced by cationic bovine serum albumin in rats

  2022influential citation
• Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population

  2019cites this paper
• DDDT_A_204974 2305..2330

  2019cites this paper
• Cordyceps militaris fruit body extract ameliorates membranous glomerulonephritis by attenuating oxidative stress and renal inflammation via the NF-κB pathway.

  2016cites this paper
• A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

  2015cites this paper
• IL-4, IL-10 and TNF-α Polymorphisms in Idiopathic Membranous Nephropathy (IMN)

  2015cites this paper
• Effect of Add-on Pentoxifylline on Proteinuria in Membranous Glomerulonephritis: A 6-month Placebo-controlled Trial

  2013cites this paper
• Skimmin, a Coumarin from Hydrangea paniculata, Slows down the Progression of Membranous Glomerulonephritis by Anti-Inflammatory Effects and Inhibiting Immune Complex Deposition

  2013cites this paper
• Depletion of B Lymphocytes in Idiopathic Membranous Glomerulopathy: Results from Patients with Extended Follow-Up

  2013cites this paper
• A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.

  2011cites this paper
• Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study.

  2009cites this paper
• What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy?

  2008cites this paper
• A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.

  2007cites this paper
• TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy.

  2007cites this paper
• What is new in therapy of glomerulonephritis in 2003/2004.

  2004cites this paper